CD4 T cell count is inversely associated with lumbar spine bone mass in HIV-infected men under the age of 50 years
- 234 Downloads
HIV-infected men under the age of 50 years had a lower bone mass compared to that of HIV-uninfected men. Lower CD4 T cell counts, independent of whether antiretroviral therapy (ART) was used, were associated with lower BMD. HIV-infected patients with low CD4 T cell counts may need follow-up and intervention regarding bone health, including younger patients.
HIV-infected patients have a low bone mineral density (BMD) owing to multifactorial interaction between common osteoporosis risk factors and HIV-related factors, including chronic inflammation and ART. Although HIV infection and ART might affect bone metabolism, little data is available for patients aged under 50 years. We aimed to investigate the association of HIV infection-induced low CD4 T cell counts and ART with BMD in men aged under 50 years.
We performed an age- and body mass index–matched case–control study. BMD values of HIV-infected and HIV-uninfected men (< 50 years) were compared, and HIV-infected men were stratified by CD4 T cell counts and ART use.
After adjusting confounders, HIV-infected men with CD4 T cell counts ≥ 500 cells/μL (n = 28) and < 500 cells/μL (n = 139) had lower BMD at the femoral neck (FN, p < 0.001) and total hip (TH, p < 0.001) than HIV-uninfected men (n = 167). HIV-infected men with CD4 T cell counts < 500/μL had lower BMD at the lumbar spine (LS, p = 0.034) than those with counts of ≥ 500 cells/μL, but not at FN and TH. The CD4 T cell count (γ = 0.169, p = 0.031) was positively correlated with BMD at LS. There was no significant difference in the BMD (p = 0.499–> 0.999) between the ART-naïve (n = 75) and ART-user group (n = 92).
Despite their relatively younger age, HIV-infected men had a lower BMD than HIV-uninfected men. Lower CD4 T cell counts, irrespective of ART, might result in lower bone mass.
KeywordsBone mineral density CD4 T cell counts HIV infection
We express our sincere gratitude to Suyeon Park, M.S. (Department of Biostatistics, Soonchunhyang University Seoul Hospital, Seoul, Republic of Korea) for her valuable assistance with the statistical analysis.
This study was supported by grants from the Asan Institute for Life Sciences, Seoul, Republic of Korea (Project Nos. 2016-568 and 2017-568).
Compliance with ethical standards
This study was approved by the Institutional Review Board (IRB) of Soonchunhyang University, Seoul Hospital (Seoul, Republic of Korea) (IRB no. 2017-03-014). The requirement for written informed consent from patients was waived due to the retrospective nature of the study and its impracticability.
Conflicts of interest
- 6.Organization WH (2016) Progress report 2016: prevent HIV, test and treat all: WHO support for country impactGoogle Scholar
- 10.Fakruddin JM, Laurence J (2003) HIV envelope gp120-mediated regulation of osteoclastogenesis via receptor activator of nuclear factor kappa B ligand (RANKL) secretion and its modulation by certain HIV protease inhibitors through interferon-gamma/RANKL cross-talk. J Biol Chem 278:48251–48258. https://doi.org/10.1074/jbc.M304676200 CrossRefGoogle Scholar
- 12.Cotter EJ, Malizia AP, Chew N, Powderly WG, Doran PP (2007) HIV proteins regulate bone marker secretion and transcription factor activity in cultured human osteoblasts with consequent potential implications for osteoblast function and development. AIDS Res Hum Retrovir 23:1521–1530. https://doi.org/10.1089/aid.2007.0112 CrossRefGoogle Scholar
- 13.Vikulina T, Fan X, Yamaguchi M, Roser-Page S, Zayzafoon M, Guidot DM, Ofotokun I, Weitzmann MN (2010) Alterations in the immuno-skeletal interface drive bone destruction in HIV-1 transgenic rats. Proc Natl Acad Sci U S A 107:13848–13853. https://doi.org/10.1073/pnas.1003020107 CrossRefGoogle Scholar
- 14.Yun TJ, Chaudhary PM, Shu GL, Frazer JK, Ewings MK, Schwartz SM, Pascual V, Hood LE, Clark EA (1998) OPG/FDCR-1, a TNF receptor family member, is expressed in lymphoid cells and is up-regulated by ligating CD40. J Immunol 161:6113–6121Google Scholar
- 17.Aukrust P, Haug CJ, Ueland T, Lien E, Muller F, Espevik T, Bollerslev J, Froland SS (1999) Decreased bone formative and enhanced resorptive markers in human immunodeficiency virus infection: indication of normalization of the bone-remodeling process during highly active antiretroviral therapy. J Clin Endocrinol Metab 84:145–150. https://doi.org/10.1210/jcem.84.1.5417 Google Scholar
- 18.Ofotokun I, Titanji K, Vunnava A, Roser-Page S, Vikulina T, Villinger F, Rogers K, Sheth AN, Lahiri CD, Lennox JL, Weitzmann MN (2016) Antiretroviral therapy induces a rapid increase in bone resorption that is positively associated with the magnitude of immune reconstitution in HIV infection. Aids 30:405–414. https://doi.org/10.1097/qad.0000000000000918 CrossRefGoogle Scholar
- 19.McComsey GA, Kitch D, Daar ES, Tierney C, Jahed NC, Tebas P, Myers L, Melbourne K, Ha B, Sax PE (2011) Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG A5202. J Infect Dis 203:1791–1801. https://doi.org/10.1093/infdis/jir188 CrossRefGoogle Scholar
- 26.Kitahata MM, Gange SJ, Abraham AG, Merriman B, Saag MS, Justice AC, Hogg RS, Deeks SG, Eron JJ, Brooks JT, Rourke SB, Gill MJ, Bosch RJ, Martin JN, Klein MB, Jacobson LP, Rodriguez B, Sterling TR, Kirk GD, Napravnik S, Rachlis AR, Calzavara LM, Horberg MA, Silverberg MJ, Gebo KA, Goedert JJ, Benson CA, Collier AC, van Rompaey SE, Crane HM, McKaig RG, Lau B, Freeman AM, Moore RD (2009) Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med 360:1815–1826. https://doi.org/10.1056/NEJMoa0807252 CrossRefGoogle Scholar
- 29.McDermott AY, Terrin N, Wanke C, Skinner S, Tchetgen E, Shevitz AH (2005) CD4+ cell count, viral load, and highly active antiretroviral therapy use are independent predictors of body composition alterations in HIV-infected adults: a longitudinal study. Clin Infect Dis 41:1662–1670. https://doi.org/10.1086/498022 CrossRefGoogle Scholar
- 31.Gazzola L, Savoldi A, Bai F, Magenta A, Dziubak M, Pietrogrande L, Tagliabue L, del Sole A, Bini T, Marchetti G, d’Arminio Monforte A (2015) Assessment of radiological vertebral fractures in HIV-infected patients: clinical implications and predictive factors. HIV Med 16:563–571. https://doi.org/10.1111/hiv.12267 CrossRefGoogle Scholar
- 32.Porcelli T, Gotti D, Cristiano A, Maffezzoni F, Mazziotti G, Foca E, Castelli F, Giustina A, Quiros-Roldan E (2014) Role of bone mineral density in predicting morphometric vertebral fractures in patients with HIV infection. Osteoporos Int 25:2263–2269. https://doi.org/10.1007/s00198-014-2760-z CrossRefGoogle Scholar
- 33.Borderi M, Calza L, Colangeli V, Vanino E, Viale P, Gibellini D, Re MC (2014) Prevalence of sub-clinical vertebral fractures in HIV-infected patients. New Microbiol 37:25–32Google Scholar
- 38.Casado JL (2016) Renal and bone toxicity with the use of Tenofovir: understanding at the end. AIDS Rev 18:59–68Google Scholar
- 39.Sudjaritruk T, Bunupuradah T, Aurpibul L, Kosalaraksa P, Kurniati N, Prasitsuebsai W, Sophonphan J, Ananworanich J, Puthanakit T (2016) Hypovitaminosis D and hyperparathyroidism: effects on bone turnover and bone mineral density among perinatally HIV-infected adolescents. Aids 30:1059–1067. https://doi.org/10.1097/qad.0000000000001032 CrossRefGoogle Scholar